Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Johnson & Johnson’s Clock 12% Q4 Revenue Growth, Cancer and Crohn’s Disease Drugs Account as Largest Sellers
Johnson & Johnson's Q4 2023 performance, with adjusted earnings up 11.7%, sales at $21.4 billion, and key insights into pharmaceutical and MedTech segments.
The Biden-Harris Administration Announces New Guidance To Enable Expanded Access To All FDA-Approved Contraceptives Without Cost
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to
Artelo Biosciences Announces Publication Of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness In Treating And Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological
Corbus Pharmaceuticals Announces Phase 1 Clinical Data For SYS6002 To Be Presented At 2024 ASCO GU
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the
Bristol Myers Squibb’s Combo Therapy Shows Sustained Benefits Over Pfizer’s Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight years.
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Rezolute Receives Innovation Passport Designation From The U.K. Innovative Licensing And Access Pathway Steering Group For RZ358 In The Treatment Of Hypoglycemia Due To Congenital Hyperinsulinism
Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K.
bioAffinity Technologies Announces Award Of Therapeutic Patent For Treatment Of Cancer; Indian Patent Office Grants Patent Related To Porphyrin Compounds For Targeted Cancer Treatment
Indian Patent Office Grants Patent Related to Porphyrin Compounds for Targeted Cancer TreatmentbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate
AngioDynamics Announces FDA 510(k) Clearance Of Auryon XL Radial Access Catheter To Treat Peripheral Arterial Disease
225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient RecoveryAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical